Find information on thousands of medical conditions and prescription drugs.

Esophageal varices

In medicine (gastroenterology), esophageal varices are extreme dilations of sub-mucosal veins in the mucosa of the esophagus in diseases featuring portal hypertension, secondary to cirrhosis primarily. more...

Home
Diseases
A
B
C
D
E
Ebola hemorrhagic fever
Ebstein's anomaly
Eclampsia
Ectodermal Dysplasia
Ectopic pregnancy
Ectrodactyly
Edwards syndrome
Ehlers-Danlos syndrome
Ehrlichiosis
Eisoptrophobia
Elective mutism
Electrophobia
Elephantiasis
Ellis-Van Creveld syndrome
Emetophobia
Emphysema
Encephalitis
Encephalitis lethargica
Encephalocele
Encephalomyelitis
Encephalomyelitis, Myalgic
Endocarditis
Endocarditis, infective
Endometriosis
Endomyocardial fibrosis
Enetophobia
Enterobiasis
Eosinophilia-myalgia...
Eosinophilic fasciitis
Eosophobia
Ependymoma
Epicondylitis
Epidermolysis bullosa
Epidermolytic hyperkeratosis
Epididymitis
Epilepsy
Epiphyseal stippling...
Epistaxiophobia
EPP (erythropoietic...
Epstein barr virus...
Equinophobia
Ergophobia
Erysipelas
Erythema multiforme
Erythermalgia
Erythroblastopenia
Erythromelalgia
Erythroplakia
Erythropoietic...
Esophageal atresia
Esophageal varices
Esotropia
Essential hypertension
Essential thrombocythemia
Essential thrombocytopenia
Essential thrombocytosis
Euphobia
Evan's syndrome
Ewing's Sarcoma
Exencephaly
Exophthalmos
Exostoses
Exploding head syndrome
Hereditary Multiple...
Hereditary Multiple...
Hereditary Multiple...
Hereditary Multiple...
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Patients with esophageal varices have a strong tendency to develop bleeding.

Esophageal varices are disagnosed with endoscopy.

Treatment

In emergency situations, the care is directed at stopping blood loss, and maintaining plasma volume.

  • banding
  • sclerotherapy

Prevention

Ideally, patients with known varices should receive treatment to reduce their risk of bleeding (Lebrec et al., 1981). The non-selective β-blockers (e.g., propranolol, timolol or nadolol). The effectiveness of this treatment has been shown by a number of different studies (Talwalkar JA & Kamath PS, 2004).

Unfortunately, non-selective β-blockers do not prevent the formation of esophageal varices (Groszmann RJ et al., 2005).

Read more at Wikipedia.org


[List your site here Free!]


Varices - Portal Hypertension, part 1 - ABC of Diseases of Liver, Pancreas, and Biliary System
From British Medical Journal, 2/10/01 by J E J Krige

ABC of diseases of liver, pancreas, and biliary system

The portal vein carries about 1500 ml/min of blood from the small and large bowel, spleen, and stomach to the liver at a pressure of 5-10 mm Hg. Any obstruction or increased resistance to flow or, rarely, pathological increases in portal blood flow may lead to portal hypertension with portal pressures over 12 mm Hg. Although the differential diagnosis is extensive, alcoholic and viral cirrhosis are the leading causes of portal hypertension in Western countries, whereas liver disease due to schistosomiasis is the main cause in other areas of the world. Portal vein thrombosis is the commonest cause in children.

Increases in portal pressure cause development of a portosystemic collateral circulation with resultant compensatory portosystemic shunting and disturbed intrahepatic circulation. These factors are partly responsible for the important complications of chronic liver disease, including variceal bleeding, hepatic encephalopathy, ascites, hepatorenal syndrome, recurrent infection, and abnormalities in coagulation. Variceal bleeding is the most serious complication and is an important cause of death in patients with cirrhotic liver disease.

Varices

In Western countries variceal bleeding accounts for about 7% of episodes of gastrointestinal bleeding, although this varies according to the prevalence of alcohol related liver disease (11% in the United States, 5% in the United Kingdom). Patients with varices have a 30% lifetime risk of bleeding, and a third of those who bleed will die. Patients who have bled once from oesophageal varices have a 70% chance of bleeding again, and about a third of further bleeding episodes are fatal.

Several important considerations influence choice of treatment and prognosis. These include the natural course of the disease causing portal hypertension, location of the bleeding varices, residual hepatic function, presence of associated systemic disease, continuing drug or alcohol misuse, and response to specific treatment. The modified Child-Pugh classification identifies three risk categories that correlate well with survival.

Initial measures

Prompt resuscitation and restoration of circulating blood volume is vital and should precede any diagnostic studies. While their blood is being cross matched, patients should receive a rapid infusion of 5% dextrose and colloid solution until blood pressure is restored and urine output is adequate. Saline infusions may aggravate ascites and must be avoided. Patients who are haemodynamically unstable, elderly, or have concomitant cardiac or pulmonary disease should be monitored by using a pulmonary artery catheter as injudicious administration of crystalloids, combined with vasoactive drugs, can lead to the rapid onset of oedema, ascites, and hyponatraemia. Concentrations of clotting factors are often low, and fresh blood, fresh frozen plasma, and vitamin [K.sub.1] (phytomenadione) should be given. Platelet transfusions may be necessary. Sedatives should be avoided, although haloperidol is useful in patients with symptoms of alcohol withdrawal.

Pharmacological control

Drag treatment, aimed at controlling the acute bleed and facilitating diagnostic endoscopy and emergency sclerotherapy, may be useful when variceal bleeding is rapid. Octreotide, a synthetic somatostatin analogue, reduces splanchnic blood flow when given intravenously as a constant infusion (50 [micro]g/h) and can be used before endoscopy in patients with active bleeding. Vasopressin (0.4 units/min), or the long acting synthetic analogue terlipressin, combined with glyceryl trinitrate administered intravenously or transdermally through a skin patch is also effective but has more side effects than octreotide. Glyceryl trinitrate reduces the peripheral vasoconstriction caused by vasopressin and has an additive effect in lowering portal pressure.

Emergency endoscopy

Emergency diagnostic fibreoptic endoscopy is essential to confirm that oesophageal varices are present and are the source of bleeding. Most patients will have stopped bleeding spontaneously before endoscopy (60% of bleeds) or after drug treatment. Endotracheal intubation may be necessary during endoscopy, especially in patients who are bleeding heavily, encephalopathic, or unstable despite vigorous resuscitation. In 90% of patients variceal bleeding originates from oesophageal varices. These are treated by injection with sclerosant or by banding.

Sclerotherapy

In sclerotherapy a sclerosant solution (ethanolamine oleate or sodium tetradecyl sulphate) is injected into the bleeding varix or the overlying submucosa. Injection into the varix obliterates the lumen by thrombosis whereas injection into the submucosa produces inflammation followed by fibrosis. The first injection controls bleeding in 80% of cases. If bleeding recurs, the injection is repeated. Complications are related to toxicity of the sclerosant and include transient fever, dysphagia and chest pain, ulceration, stricture, and (rarely) perforation.

Band ligation

Band ligation is achieved by a banding device attached to the tip of the endoscope. The varix is aspirated into the banding chamber, and a trip wire dislodges a rubber band carried on the banding chamber, ligating the entrapped varix. One to three bands are applied to each varix, resulting in thrombosis. Band ligation eradicates oesophageal varices with fewer treatment sessions and complications than sclerotherapy.

Balloon tube tamponade

The balloon robe tamponade may be life saving in patients with active variceal bleeding if emergency sclerotherapy or banding is unavailable or not technically possible because visibility is obscured. In patients with active bleeding, an endotracheal tube should be inserted to protect the airway before attempting to place the oesophageal balloon robe.

The Minnesota balloon tube has four lumens, one for gastric aspiration, two to inflate the gastric and oesophageal balloons, and one above the oesophageal balloon for suction of secretions to prevent aspiration. The robe is inserted through the mouth, and correct siting within the stomach is checked by auscultation while injecting air through the gastric lumen. The gastric balloon is then inflated with 200 ml of air. Once fully inflated, the gastric balloon is pulled up against the oesophagogastric junction, compressing the submucosal varices. The tension is maintained by strapping a split tennis ball to the tube at the patient's mouth.

The oesophageal balloon is rarely required. The main complications are gastric and oesophageal ulceration, aspiration pneumonia, and oesophageal perforation. Continued bleeding during balloon tamponade indicates an incorrectly positioned tube or bleeding from another source. After resuscitation, and within 12 hours, the tube is removed and endoscopic treatment repeated.

Alternative management

Transjugular intrahepatic portosystemic shunt

Transjugular intrahepatic portosystemic shunt is the best procedure for patients whose bleeding is not controlled by endoscopy. It is effective only in portal hypertension of hepatic origin. The procedure is performed via the internal jugular vein under local anaesthesia with sedation. The hepatic vein is cannulated and a tract created through the liver parenchyma from the hepatic to the portal vein, with a needle under ultrasonographic and fluoroscopic guidance. The tract is dilated and an expandable metal stent inserted to create an intrahepatic portosystemic shunt. The success rate is excellent. Haemodynamic effects are similar to those found with surgical shunts, with a lower procedural morbidity and mortality.

Transjugular intrahepatic portosystemic shunting is an effective salvage procedure for stopping acute variceal haemorrhage, controlling bleeding from gastric varices, and congestive gastropathy after failure of medical and endoscopic treatment. However, because encephalopathy occurs in up to 25% of cases and up to 50% of shunts may occlude by one year, its primary role is to rescue failed endoscopy or as a bridge to subsequent liver transplantation.

Long term management

Alter the acute variceal haemorrhage has been controlled, treatment should be initiated to prevent rebleeding, which occurs in most patients.

Repeated endoscopic treatment

Repeated endoscopic treatment eradicates oesophageal varices in most patients, and provided that follow up is adequate serious recurrent variceal bleeding is uncommon. Because the underlying portal hypertension persists, patients remain at risk of developing recurrent varices and therefore require lifelong regular surveillance endoscopy.

Long term drug treatment

The use of [Beta] blockers after variceal bleeding has been shown to reduce portal blood pressures and lower the risk of further variceal bleeding. All patients should take [Beta] blockers unless they have contraindications. Best results are obtained when portal blood pressure is reduced by more than 20% of baseline or to below 12 mm Hg.

Surgical procedures

Patients with good liver function in whom endoscopic management fails or who live far from centres where endoscopic sclerotherapy services are available are candidates for surgical shunt procedures. A successful portosystemic shunt prevents recurrent variceal bleeding but is a major operation that may cause further impairment of liver function. Partial portacaval shunts with 8 mm interposition grafts are equally effective to other shunts in preventing rebleeding and have a low rate of encephalopathy.

Oesophageal transection and gastric devascularisation are now rarely performed but have a role in patients with portal and splenic vein thrombosis who are unsuitable for shunt procedures and continue to have serious variceal bleeding despite endoscopic and drug treatment.

Liver transplantation is the treatment of choice in advanced liver disease. Hepatic decompensation is the ultimate decompressive shunt for portal hypertension and also restores liver function. Transplantation treats other complications of portal hypertension and has one year and five year survival rates of 80% and 60% respectively.

Prophylactic management

Most patients with portal hypertension never bleed, and it is difficult to predict who will. Attempts at identifying patients at high risk of variceal haemorrhage by measuring the size or appearance of varices have been largely unsuccessful. [Beta] blockers have been shown to reduce the risk of bleeding, and all patients with varices should take them unless contraindicated.

Gastric varices and portal hypertensive gastropathy

Gastric varices are the source of bleeding in 5-10% of patients with variceal haemorrhage. Higher rates are reported in patients with left sided portal hypertension due to thrombosis of the splenic vein. Endoscopic control of gastric varices is difficult unless they are located on the proximal lesser curve in continuation with oesophageal varices. Endoscopic administration of cyanoacrylate monomer (superglue) is useful for gastric varices. The transjugular intrahepatic portosystemic shunt is increasingly used to control bleeding in this group.

Bleeding from portal hypertensive gastropathy accounts for 2-3% of bleeding episodes in cirrhosis. Although serious bleeding from these sources is uncommon, when it occurs its diffuse nature precludes the use of endoscopic treatment, and optimal management is with a combination of terlipressin and [Beta] blockers.

Causes of portal hypertension

Increased resistance to flow

Prehepatic (portal vein obstruction)

* Congenital atresia or stenosis

* Thrombosis of portal vein

* Thrombosis of splenic vein

* Extrinsic compression (for example, tumours)

Hepatic

* Cirrhosis

* Acute alcoholic liver disease

* Congenital hepatic fibrosis

* Idiopathic portal hypertension (hepatoportal sclerosis)

* Schistosomiasis

Posthepatic

* Budd-Chiari syndrome

* Constrictive pericarditis

Increased portal blood flow

* Arterial-portal venous fistula

* Increased splenic flow

Summary points

* Variceal bleeding is an important cause of death in cirrhotic patients

* Acute management consists of resuscitation and control of bleeding by sclerotherapy or balloon tamponade

* After a bleed patients require treatment to eradicate varices and lifelong surveillance to prevent further bleeds

* All patients with varices should take [Beta] blockers to reduce the risk of bleeding unless contraindicated by coexisting medical conditions

* Surgery is now rarely required for acute or chronic control of variceal bleeding

Child-Pugh classification of liver failure

Grade A = 5-6 points, grade B = 7-9, grade C = 10-15 points.

Further reading

Krige JEJ, Terblanche J. Endoscopic therapy in the management of oesophageal varices: injection sclerotherapy and variceal injection. In: Blumgart LH, ed. Surgery of the liver and biliary tract. London: Saunders, 2000:1885-1906

Sherlock S, Dooley J. Portal hypertension. In: Diseases of the liver and biliary system. Oxford: Blackwell Science, 1996

Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999;340:988-93

J E J Krige is associate professor of surgery, Groote Schuur Hospital and University of Cape Town, South Africa.

The ABC of diseases of liver, pancreas, and biliary system is edited by I J Beckingham, consultant hepatobiliary and laparoscopic surgeon, department of surgery, Queen's Medical Centre, Nottingham (Ian.Beckingham@nottingham.ac.uk). The series will be published as a book later this year.

BMJ 2001;322:348-51

COPYRIGHT 2001 British Medical Association
COPYRIGHT 2001 Gale Group

Return to Esophageal varices
Home Contact Resources Exchange Links ebay